Predictors of CD4 count changes over time among children who initiated highly active antiretroviral therapy in Ethiopia

Tilahun Yemanu Birhan, Lemma Derseh Gezie, Destaw Fetene Teshome and Malede Mequanent Sisay*

Abstract

Introduction: Human immunodeficiency virus (HIV) infection results in a gradual depletion of immune function, particularly CD4 cells. The CD4 assessment plays a significant role in assessing treatment responses and clinical decision-making for patients on combination antiretroviral therapy (ART) in resource-limited settings. However, new data on CD4 count changes are scarce; the volatility of CD4 counts after initiation of ART over time remains largely uncharacterized. This study aimed to identify the predictors of CD4 changes over time among HIV-infected children who began ART in Amhara, Ethiopia.

Methods: A retrospective follow-up study was performed. A total of 983 HIV-infected children who initiated ART in government hospitals in the Amhara region between 2010 and 2016 were included using a simple random sampling technique. Data were extracted using a structured checklist. An exploratory data analysis was carried out to explain individual and average profile plots. The linear mixed model was used to identify the CD4 change count predictors over time. Variables with $p$ value $< 0.05$ were considered statistically significant in a multivariable linear mixed regression analysis.

Results: The mean CD4 count of the participants was 465.1 cells/mm$^3$ with an average CD4 count increase of 30.06 cells/mm$^3$ over 6 months from baseline CD4 count and ART initiation. Childhood age ($\beta = -0.015; 95\%$ CI $-0.021$, $-0.009$), opportunistic infection at ART initiation ($\beta = -0.044, 95\%$ CI $-0.085$, $-0.004$), hemoglobin level ($\beta = 0.013; 95\%$ CI $0.004$, $0.022$), and baseline WHO clinical stage II ($\beta = -0.046, 95\%$ CI $-0.091$, $-0.0003$) were significant predictors of CD4 changes over time.

Conclusions: The average CD4 count increase was sufficient in HIV patients who began combined antiretroviral therapy over time. The younger age of the infant, the higher baseline level of hemoglobin, the baseline WHO clinical stage II, and opportunistic infections led to changes in CD4 counts. As a result, timely diagnosis and treatment of opportunistic infections will reduce the risk of opportunistic infections.

Keywords: Highly active antiretroviral therapy, Child, HIV, Modeling, Risk factors, Sub-Sahara Africa

Introduction

Human immunodeficiency virus infection results in a gradual decline in immune function, especially in critical immune cells called CD4 [1]. Highly active antiretroviral therapy, the key component of the HIV treatment strategy, is intended to inhibit HIV replication [2], restore and/or sustain immune functions or CD4 cells [3], and enhance the quality of life of infected patients [4]. Evidence has shown that sufficient CD4 response in most patients with ART is considered when there is a rise in the range of 50–150 cells/mm$^3$ per year with an accelerated response in the first 3 months of treatment before a steady-state level is reached [5]. Nevertheless, absolute CD4 counts can fluctuate within individuals,
and some patients may not have an adequate CD4 count recovery due to reasons other than poor ART response. Previous studies indicated that ART initiation at an older age [6], baseline low CD4 count [6–9], and WHO clinical stages III and IV [10] were correlated with lower CD4 count recovery. Other observational studies have found that opportunistic infections [11, 12], presence of chronic diarrhea [13], low baseline hemoglobin level [13], poor adherence to drugs [14], poor functioning status [15], and low body mass index (BMI) [16, 17] at baseline were significantly allied with weak CD4 count shifts. As a result, children with low CD4 counts are at an elevated risk for adverse effects, such as growth retardation [18], drug resistance [19], and the onset of other opportunistic infectious diseases [20–23] and death [24].

Monitoring of CD4 counts of patients on ART is highly recommended for analysis of reactions to care and clinical decision-making in resource-limited settings [19, 25]. However, there is limited evidence of improvements in CD4 counts and related factors among children in HIV care and treatment programs in Ethiopia. The heterogeneity of CD4 cell counts after the initiation of ART over time remains largely uncharacterized, and most published works do not identify factors related to their heterogeneity with long-term use of ART in the country. The goal of this study was therefore to identify the predictors of CD4 cell count changes over time among HIV-infected children under 15 years of age who initiated ART in public hospitals in the Amhara region of Ethiopia.

Methods
Study design and period
A retrospective follow-up study was conducted among HIV-infected pediatric patients (< 15 years of age) who initiated ART from January 2010 to February 2016.

Study area and population
The study was conducted in government hospitals in Amhara National Regional State. The region is the second most populated, with an estimated total population of 19,602,512, situated in the northwest of Ethiopia. The region has 19 public hospitals, 801 health centers, 3302 health institutions, and 1031 private health facilities (clinics and hospitals). All public hospitals offer ART services to adults and children of Amhara and neighboring areas. According to the Amhara Regional Health Office survey, more than 2112 pediatric HIV-infected patients were successfully enrolled in ART in these hospitals and clinics in 2018. The study population included HIV-positive children who began ART therapy in these public referral hospitals. However, children were removed from the study if they were under 6 months of age because the response to HIV treatment should be satisfactory after 6 months of follow-up.

Sample size and sampling procedure
The sample size was determined using the following assumptions; all subjects measured at \( m = 8 \) time points (no dropout), constant within-subject correlation \( (\rho = 0.5, \sigma^2 = 1) \), 90% power, a difference of 0.25 at the two-sided test, and 95% confidence interval (CI).

\[
\begin{align*}
\text{Sample size} & = 4 \sigma^2(1 + (m-1)\rho)(Z_{a/2} + Z_{\alpha/4})^2 \\
& = 4(1 + (7)0.5)(1.96 + 1.645)^2 \\
& = 467.86 \approx 468
\end{align*}
\]

Given the effect size of two and the incomplete rate of 5%, the total sample (983) was included in the analysis. The research was performed in six out of 19 public hospitals, chosen based on their substantial proportion of patients served. The sample was then allocated proportionately to the selected hospitals, namely the University of Gondar Specialized, Debre Markos, Debre Birhan, Dessie referral, Felege Hiwot specialized, and Debre Tabor general hospitals for the sake of representativeness. Using the pediatric ART registration book, we have created a sampling frame for each hospital using the list of all children on ART and aged 6 months to 15 years.

Data collection tools and procedures
Pre-tested standardized data collection checklist built based on HIV/ART intake forms to retrieve routinely collected data from pediatric HIV patients who started ART in selected hospitals. The outcome variable is the CD4 count for selected participants, which is measured repeatedly over time for each person. These are repeated observations on individuals allowing a direct analysis of the transition from the baseline in which a single subject appears to be interrelated. Present literature guides the choice of explanatory variables. Variables have been grouped into the following categories: sociodemographic and clinical variables reported at ART entry and follow-up by ART clinics including sex, age, baseline CD4 count, baseline weight, regimen type, WHO stage, functional status, baseline hemoglobin level, disclosure, mother ARV status, and time in months. Basic demographic and clinical data were collected from medical records and time-dependent covariates such as CD4 count (mm\(^3\)), viral load, and weight (kg) were assessed almost every 6 months by ART nurses from each participant. Six nurses working at the ART clinic were hired as data collectors and extracted the data after they had been trained for 2 days. The data collection process was supervised by three supervisors. Data processing took place in private rooms. The collected data were reviewed...
regularly for completeness and corrected by the main investigator and the supervisors.

Data processing and analysis
The data were entered in Epi Info 7 and exported to STATA14 for analysis. Descriptive figures, such as numbers, percentages, measures, standard deviations, and quartiles were used to describe children’s characteristics. Besides, we performed an exploratory review of the data to direct our modeling process. Logarithmic transformation was implemented to get rid of skewness in CD4 data and all analyses were performed using transformed result data.

Individual profile plots were constructed on the first 100 subjects to provide a rough image of how subjects evolved and to provide explanations for variation between and within subjects. Also, this study presented ideas on random effects, beginning with an overview. Average profile plots were constructed to explain the overall mean shift in CD4 count. From this study, indications were obtained as to the functional type of the transition, and the transition depended on certain characteristics of the covariates. Not all measurements were uniformly spaced around different subjects, as a result of which smoothing was applied using the LOWESS process.

With a continuous outcome variable, the linear mixed model was used to control the longitudinal nature of the data. First, the null model only/unconditional linear model containing the random effect was fitted; then the fixed intercept and slope were fitted. Next, a model containing fixed covariates was implemented to illustrate the variability of the CD4 cell count. The three structures (identity, interchangeable, and unstructured) were built to choose the covariance structure that better matches the data and thus reduces the probability of model misspecification. Finally, the one with the lowest Akaike information criteria value was chosen.

To assess the factors associated with changes in CD4 cell count, a univariate analysis of the linear mixed model was tested for each baseline factor, and those considered to be significant (p value < 0.2) were chosen for the multivariable linear mixed regression model. The linear mixed model was favored over the generalizing estimated equation because we were interested in the subject-specific effect rather than the average population effect. Besides, the maximum likelihood parameter estimation approach was used.

Results
Demographic characteristics of participants
Out of a total of 983 HIV-infected children chosen for the study, 951 (96.74%) cases were examined with complete baseline data. The mean age of baseline participants was 6.5 (SD = 3.8) years with an average follow-up period of 21.31 (SD = 18.75) months. Of the total participants, 509 (53.5%) were male and 731 (76.6%) were primary caregivers for babies, mainly biological mothers (Table 1).

Clinical characteristics
Of the patients, 286 (29.9%) were at baseline in WHO clinical stage I; 323 (33.86%) had functional status and 691 (72.8%) had opportunistic infections (Table 2). The mean weight of the participants at baseline was 19.13 kg (SD = 9.50 kg).

Baseline laboratory characteristics
The mean baseline hemoglobin levels and CD4 counts of the study participants were 12.4 mg/dl (SD = 4.15) and 465.1 (SD = 398.3) cells/mm$^3$, respectively. Furthermore, the mean rise in CD4 counts for children was 30.06 cells/mm$^3$ per 6 months or 60.12 cells/mm$^3$ per year.

CD4 count changes after initiating ART

Mean profile plot stratified by age
In general, the average profiles of the first 100 patients showed signs of variation between and within subjects. The subjects had more variable CD4 values at the beginning and adjustments over time. This indicates that a theoretical linear mixed model with random intercepts and random slopes may be feasible starting points (Fig. 1).

Mean profile plot
The average change in CD4 counts over time showed a dramatic rise in the first 20 months, followed by a modest increase of up to 40 months. In the end, it remained constant from the 40th to the last month. It is evident that the total mean CD4 count increased over time and remained constant over time (Fig. 2).

Predictors of CD4 count changes over time
Throughout the modeling process, random intercept and random slopes were assumed to compensate for individual differences in CD4 cell count at baseline and over time, respectively. Also, random and fixed effects were calculated by comparing various covariance structures.
In this case, the unstructured covariance structure offered the smallest information criterion and selected a random effect parameter model (Table S1 and S2). The values obtained from the study of the average logCD4 count of children at baseline were therefore 2.76, excluding covariate effects. The multivariable linear mixed model found covariates such as age, opportunistic infections, baseline WHO clinical stage II, and baseline hemoglobin levels were significantly correlated with CD4 count changes over time, while sex, HIV status, regimen type, adherence to medications, and maternal ARV status did not significantly affect CD4 cell count changes over time.

Age was closely correlated with CD4 cell count changes suggesting that the average logCD4 count decreased by 0.015 ($\beta = -0.015$, 95% CI $-0.021$, $-0.009$) for every 1 year rise in children’s age. At baseline, the mean logCD4 count among children who had opportunistic infection was 0.044 ($\beta = -0.044$; 95% CI $-0.085$, $-0.004$) times lower than the mean logCD4 count among children who had no opportunistic infection. Patients who began ART at WHO clinical stage II reported smaller increases in CD4 counts relative to those who began ART at the first stage. Moreover, the WHO stage negative coefficients indicate that their mean CD4 counts at baseline are significantly lower than the reference group ($p < 0.001$ for stage II vs. stage I). Baseline hemoglobin levels had a major positive impact on

---

**Table 2** Clinical and medication characteristics of study participants in the Amhara region public hospitals (2010–2016)

| Variable            | Category     | Number | %   |
|---------------------|--------------|--------|-----|
| Regimen type        | d4T + 3TC + NVP | 327    | 34.3|
|                     | d4T + 3TC + EFV | 76     | 8.0 |
|                     | AZT + 3TC + NVP | 333    | 34.9|
|                     | AZT + 3TC + EFV | 160    | 16.8|
|                     | Others        | 55     | 5.8 |
| Functional status   | Working       | 323    | 33.9|
|                     | Ambulatory    | 462    | 48.4|
|                     | Bedridden     | 166    | 17.5|
| BWHO stage          | Stage I       | 286    | 29.9|
|                     | Stage II      | 309    | 32.4|
|                     | Stage III     | 287    | 30.1|
|                     | Stage IV      | 69     | 7.2 |
| Disclosure          | Yes           | 720    | 75.7|
|                     | No            | 231    | 24.3|
| Opportunistic infection | Yes   | 691    | 72.7|
|                     | No            | 260    | 27.3|
| MARV status         | Yes           | 909    | 95.6|
|                     | No            | 42     | 4.4 |
| Medication adherence | Poor         | 291    | 38.04|
|                     | Fair          | 117    | 15.29|
|                     | Good          | 357    | 46.67|

BWHO baseline WHO stage, MARV mothers’ antiretroviral

---

![Fig. 1](image)

**Fig. 1** Smoothing mean profile plots for the logCD4 count after the initiation of ART among children in Ethiopia stratified by age from 2010 to 2016
logCD4 count. In the case of a unit increase in hemoglobin, the logCD4 count increased by 0.013 ($\beta = 0.013; 95\% \text{ CI 0.004, 0.023}$).

Time has a positive significant impact on logCD4 count ($\beta = 0.008; 95\% \text{ CI 0.007, 0.009}$) suggesting that the average logCD4 count of a person rises by 0.0058 every 6 months are compatible with other covariates (Table 3). The standard deviation for the intercept was found to be 0.276. This indicates that there is a substantial difference in intercepts between research subjects and that the evolution of CD4 counts differs across children at baseline (Table S3).

Discussion
The goal of this study was to determine the rate of CD4 count change over time and to identify its predictors among HIV-infected children who initiated ART. The individual profile plot revealed the presence of variation in CD4 counts within and between individuals. The mean profile plot also indicated that, on average, logCD4 counts appeared to increase rapidly following initiation of antiretroviral therapy. In this analysis, the average CD4 count increment was 30.06 cells/mm$^3$ per 6 months or 60.12 cells/mm$^3$ per year.

This finding is consistent with the outcome of the Swiss HIV cohort study, which found that the correct CD4 response for most patients on therapy ranged from 50 to 150 cells/mm$^3$ per year with an accelerated response in the first 3 months of treatment [5]. It may be due to the degree of suppression of viral replication, although it should be recognized that such plots are mean plots that may be different from individual plots, which may indicate that certain patients respond better than others. The study also attempted to classify the predictors of CD4 count changes over time. The age and CD4 count changes had negative associations, and the CD4 count log-odds decreased by 0.015 for a year at the age of the boy. This finding is consistent with those of studies conducted in northwest Ethiopia [15], India [26], EuroSIDA study of European countries [27], USA [28], and the Parirenyatwa Family Care Hospital [29]. It is well known that as age rises, thymic activity decreases and this will reduce CD4 counts as the thymus is the primary site of CD4 development [30]. Opportunistic infections had major negative effects on CD4 count changes over time, suggesting that children with opportunistic infections had lower CD4 counts. This is consistent with those of studies done in northwest Ethiopia [15], South Africa [31], and Korea [32]. This is because opportunistic infections improve HIV pathogenesis and further reinforce the value of prophylaxis [33].

Baseline WHO clinical stage II had a major negative impact on the CD4 count shift. As a result, the CD4 log-odds decreased by 0.0457 among HIV-infected children in stage II relative to a stage I patients. This result is consistent with the results of studies conducted in Ghana [34] and the Houston VA Special Medicine Clinic [35]. This has shown that children with more serious
Table 3 Multivariable linear mixed model analyses of factors associated with CD4 changes over time among HIV-infected children-initiated ART Amhara region public hospitals (2010–2016)

| Covariate          | Estimate  | 95% CI          | P-value |
|--------------------|-----------|-----------------|---------|
| Constant           | 2.494     | 2.328 – 2.660   |         |
| Time               | 0.008     | 0.007 – 0.009   | 0.009   |
| BMI                | 0.005     | 0.003 – 0.012   | 0.012   |
| Age                | −0.015    | −0.021 – 0.009  | 0.009   |
| Hemoglobin         | 0.013     | 0.004 – 0.022   |         |
| BW/HO stage        |           |                 |         |
| Stage I            | 0         |                 |         |
| Stage II           | −0.046    | −0.091 – 0.003  | 0.0003  |
| Stage III          | −0.039    | −0.089 – 0.011  | 0.011   |
| Stage IV           | −0.053    | −0.149 – 0.043  | 0.043   |
| Opportunistic infection | −0.044  | −0.0845 – 0.0042 | 0.0042 |
| No                 | 0         |                 |         |
| Functional status  |           |                 |         |
| Working            | 0         |                 |         |
| Ambulatory         | 0.004     | −0.036 – 0.044  | 0.044   |
| Bedridden          | 0.008     | −0.209 – 0.225  |         |
| Disclosure         |           |                 |         |
| Yes                | −0.087    | −0.129 – 0.046  |         |
| No                 | 0         |                 |         |
| Mothers ARV status |           |                 |         |
| Yes                | 0.055     | −0.019 – 0.128  | 0.128   |
| No                 | 0         |                 |         |
| Regimen type       |           |                 |         |
| d4T + 3TC + NVP    | 0         |                 |         |
| d4T + 3TC + EFV    | −0.143    | −0.217 – 0.068  |         |
| AZT + 3TC + NVP    | 0.022     | −0.020 – 0.064  |         |
| AZT + 3TC + EFV    | 0.070     | −0.017 – 0.123  |         |
| TDF + 3TC + EFV    | 0.170     | −0.010 – 0.330  |         |
| Others*            | 0.157     | −0.004 – 0.310  |         |

*TDF = 3TC + EFV, AZT + 3TC + LPV/r, ABC + 3TC + LPV/r

The limitation of the analysis is that the causal relation cannot be precisely defined due to the retrospective nature of the results, which did not contain all the necessary variables such as viral load, other clinical parameters due to lack of reagents, or technical problems. Second, the impact of CD4 counts can fluctuate due to a lack of quality and availability of data. However, since a random effect model was used, the contribution of all the variables not calculated was pooled out of the total variation to obtain the modified effect of the independent variables considered.

Conclusions
The average rate of CD4 count change was adequate in HIV patients who began combination antiretroviral therapy. The advanced age of the child, the higher baseline level of hemoglobin, the baseline WHO clinical stage II, and opportunistic infections contributed to changes in CD4 counts. As a result, early diagnosis and treatment of opportunistic infections reduce the risk of opportunistic infections. The pace of progress needs to be increased by continuing to expand universal access to ART, which can be scaled to have a population-level effect.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s41182-020-00224-9.

Additional file 1: Table S1. Selection of correlation structure for ART data set taken from the Amhara region from 2010-2016.

Additional file 2: Table S2. Random Effects Models with the associated values for the likelihood ratio test and p-value for ART data set taken from the Amhara region from 2010-2016.

Additional file 3: Table S3. Random parameter estimates for ART data set collected in the Amhara region from 2010-2016.

Abbreviations
3TC: Lamivudine; ABC: Abacavir; AIDS: Acquired immune deficiency syndrome; AIC: Akaike information criteria; ART: Antiretroviral therapy; ARV: Antiretroviral; AZT: Zidovudine; BIC: Bayesian information criteria; BMI: Body mass index; d4T: Stavudine; EFV: Efavirenz; ART: Highly active antiretroviral therapy; HIV: Human immunodeficiency virus; LMM: Linear mixed model; TDF: Tenofovir; WHO: World Health Organization

Acknowledgements
We would like to thank Gondar College of Medicine and Health Sciences for their financial support. We also thank all hospital administrators for their willingness to provide letters of access to the data. Finally, we also thank data collectors and managers for their contribution to gathering data in a well-organized manner.

Authors’ contributions
TYB participated in the design, data collection, and review of the proposals. LDG, DFT, and MMS engaged in the analysis, manuscript writing, and critical review of manuscripts. The final manuscript was read and accepted by all the contributors.

Authors’ information
TYB: lecturer in Department of Epidemiology and Biostatistics, Institute of Public Health, University of Gondar, Ethiopia; LDG: assistance professor of Biostatistics and Public Health, Institute of Public Health, University of...
Gondar, Ethiopia; DFT: lecturer in Department of Epidemiology and Biostatistics, Institute of Public Health, University of Gondar, Ethiopia; and MMS: lecturer in Department of Epidemiology and Biostatistics, Institute of Public Health, University of Gondar, Ethiopia.

Funding
The University of Gondar funds this research for collecting the data and analysis but not for publication.

Availability of data and materials
The minimal data underlying all the findings in the manuscript will be available upon request.

Ethics approval and consent to participate
Ethical approval has been received from the Institutional Review Board (IRB) of the University of Gondar. As the study was retrospective, the IRB declined to allow the work to be performed based on a record analysis without contacting the patients. However, a letter of support was obtained from the State Health Regional Office of Amhara. Permission letters were obtained from each hospital administration (University of Gondar, Felege Hiwot, Debre Tabor, Debre Markos, Debret Berhan, and Dessie) and the respective ART hospital coordinators. All information was kept secret and no personal identifiers were obtained.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Received: 9 March 2020 Accepted: 15 May 2020
Published online: 22 May 2020

References
1. Overview of HIV Infection, in Participant Manual 2005.
2. Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis. 2007, Ministry of Health & Family Welfare Government of India: NACO.
3. National guidelines for HIV testing. July 2015, National AIDS Control Organisation Ministry of Health & Family Welfare, Government of India.
4. Country progress report on the HIV response. 2014, Federal Democratic Republic of Ethiopia: Addis Ababa.
5. Kaufmann GR, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Archives of internal medicine. 2003;163(18):2187–95.
6. Gezie LD, et al. Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwestern Ethiopia. BMC research notes. 2017;10(1):277.
7. Hunt PW, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. Aids. 2003;17(13):1907–15.
8. Egger M, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet. 2002;360(9327):119–29.
9. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clinical Infectious Diseases. 2007;44(4):441–6.
10. Yirdaw KD, Hattingh S. Prevalence and predictors of immunological failure among HIV patients on HAART in Southern Ethiopia. PLoS one. 2015;10(5):e0125826.
11. Wambani J, et al. Immunological profiles in HIV positive patients with or without opportunistic infections and the influence of highly active antiretroviral therapy: a systematic review and update. J Clin Cell Immunol. 2016;7(29):2.
12. Paintsil E, et al. Absolute CD4+ T-lymphocyte count as a surrogate marker of pediatric HIV disease progression. Pediatr Infectious Dis J. 2008;27(7):629.
13. Sorsa A. Predictors of sub-optimal CD4 recovery during the first six months of anti-retroviral treatment (ART) in HIV infected children: a retrospective sectional study from Tikur Anbessa Tertiary Hospital, Addis Ababa, Ethiopia. J Blood Lymph. 2017;7(3):178.
14. Seyoum A, Temesgen Z. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region). AIDS Res Ther. 2017;14(1):14.
15. Gezie LD, et al. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwestern Ethiopia: multilevel analysis. BMC research notes. 2016;9(1):377.
16. Misseou E, et al. Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults. Bull World Health Organization. 2008;86(6):435–42.
17. Palermo B, et al. Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy. HIV Clin Trials. 2011;12(4):222–7.
18. Kabue MM, et al. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS patient care and STDs. 2008;22(3):245–51.
19. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, in recommendations for a public health approach. June 2013, World Health Organization: Geneva 27, Switzerland.
20. Müller M, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. The Lancet infectious diseases. 2010;10(4):251–61.
21. Holmes CB, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2006;42(4):464–9.
22. Murdoch DM, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. Aids. 2008;22(5):601–10.
23. Lewis J, et al. Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infectious Dis. 2011;204(5):454–55.
24. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, in PILOs medicine. 2012, Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe in EuroCoord. p. e1001194.
25. Banerjee S, et al. Association between degree of exposure to the Hospital Value Based Purchasing Program and 30-day mortality: experience from the first year of Medicare’s pay-for-performance program. BMC Health Serv Res. 2019;19(1):921.
26. Prakash, J. and D. Basavarajiah, Temporal changes of CD4+ T-Cell changes in response to highly active antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS patient care and STDs. 2017;31(8):532–53.
27. Florence E, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSida study. HIV medicine. 2003;4(3):255–62.
28. Patel K, et al. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clinical Infectious Diseases. 2008;46(11):1751–60.
29. Murenjevka, W., Comparison of CD4+ T-Cell changes in response to highly active antiretroviral therapy (HAART) in adolescents and children enrolled at Parirenyatwa Hospital Family Care Centre (2005-2010)-Secondary Data Analysis. 2013.
30. Gautier D, et al. Efficient thymopoiesis contributes to the maintenance of peripheral CD4 T cells during chronic human immunodeficiency virus type 2 infection. Journal of virology. 2007;81(22):12685–8.
31. Zanoni BC, et al. Predictors of poor CD4 and weight recovery in HIV-infected children initiating ART in South Africa. PILOs One. 2012;7(3):e33611.
32. Kim K-H, Yi J, Lee SH. The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study. The Korean journal of internal medicine. 2015;30(5):705.
33. Chaissin RE, et al. Impact of opportunistic disease on survival in patients with HIV infection. Aids. 1998;12(1):29–33.
34. Bargi O, et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. BMC infectious diseases. 2013;13(1):476.
35. Rabeneck L, et al. A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats. Journal of general internal medicine. 1993(8)(1–9).
36. Kwantwi LB, et al. Body mass index, haemoglobin, and total lymphocyte count as a surrogate for CD4 count in resource limited settings. Journal of biomarkers. 2017;2017.

37. Vanisri H, Vadiraja N. Relationship between red blood cell parameters and immune status in HIV infected females. Indian J Pathol Oncol. 2016;3(2):255–9.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.